OAK 0011799
Alternative Names: OAK-0011799Latest Information Update: 12 Mar 2024
At a glance
- Originator Blue Oak Pharmaceuticals; Exscientia
- Class Antipsychotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psychotic disorders; Schizophrenia
Most Recent Events
- 29 Feb 2024 Research in Psychotic disorders in United Kingdom (unspecified route) (Blue Oak Pharmaceuticals pipeline, February 2024)
- 29 Feb 2024 Research in Psychotic disorders in USA (unspecified route) (Blue Oak Pharmaceuticals pipeline, February 2024)
- 29 Feb 2024 Research in Schizophrenia in United Kingdom (unspecified route) (Blue Oak Pharmaceuticals pipeline, February 2024)